A5032781569- Dermatology and Skin Diseases
- Hair Growth and Disorders
- Skin Protection and Aging
- melanin and skin pigmentation
- Dermatologic Treatments and Research
- Olfactory and Sensory Function Studies
- Food Allergy and Anaphylaxis Research
- Allergic Rhinitis and Sensitization
- Herpesvirus Infections and Treatments
- Hereditary Neurological Disorders
- Asthma and respiratory diseases
- Medicine and Dermatology Studies History
- RNA regulation and disease
- Urticaria and Related Conditions
- Wound Healing and Treatments
- Dupuytren's Contracture and Treatments
Adelphi Group (United Kingdom)
2022-2025
Alopecia areata (AA) can negatively affect quality of life (QoL) and is associated with increased prevalence anxiety depression (vs people without AA). This study compared physician-assessed patient self-rated severity AA in a European sample described the patient-reported burden stratified by severity. Real-world data were collected from Adelphi Real World Disease Specific Programme™, retrospective point-in-time cross-sectional survey dermatologists their adult patients five countries...
The 2021 US approval of ruxolitinib cream for treatment atopic dermatitis (AD) in patients aged ≥ 12 years was based on the results two pivotal phase 3 studies. Currently, real-world data to describe effectiveness and physician satisfaction with remain limited. Our objective is disease control among adults mild moderate AD prescribed treatment. Data were from Adelphi Disease Specific Programme™, a real-world, cross-sectional survey physician-reported data, undertaken between August 2022...
Alopecia areata (AA) is an autoimmune condition that causes non-scarring hair loss and can impose a high psychosocial burden on patients. The presence of comorbid conditions may impact the management AA in clinical practice. This analysis aims to describe disease characteristics patients with concomitant atopic, autoimmune, psychiatric conditions. Data were collected from Adelphi Disease Specific Programme™, cross-sectional survey physicians their adult conducted France, Germany, Italy,...
ABSTRACT Background Hair loss due to alopecia areata (AA) can negatively impact patients’ health‐related quality of life (HRQoL). Patient‐reported outcome measures (PROMs) like the EQ‐5D‐5L and Alopecia Areata Patient Priority Outcomes (AAPPO) represent treatment outcomes guide decision‐making. However, potentially underestimates AA‐specific impacts, while AAPPO may provide a more disease‐specific assessment. Objectives This study uses emotional symptom (ES) activity limitations (AL)...
Vitiligo may negatively impact quality of life (QOL). This study aimed to classify patients on the basis vitiligo emotional/psychological and social functioning describe patient characteristics patient-reported outcome (PRO) responses for each profile. Physician surveys from Disease Specific Programme in France, Germany, Italy, Spain, USA were analyzed. PROs assessed using Patient Priority Outcomes (ViPPO), Work Productivity Activity Index-Vitiligo, Vitiligo-Specific Quality-of-Life...
Vitiligo was historically regarded as a cosmetic disorder; however, it is an autoimmune disease. As visible condition, affects patient well-being. We assessed the impact of disease severity, lesion location, and body surface area (BSA) affected on health-related quality life (HRQoL). Retrospective data were from Adelphi Real World Disease Specific Programme: cross-sectional survey physicians their patients with vitiligo (10/2021–07/2022). Patient-reported outcomes by Vitiligo-Specific...
There is currently a lack of research regarding disease course and burden as well treatment patterns goals in patients with non-segmental vitiligo (NSV). The aim this analysis was to evaluate course, NSV. This used secondary data from the Adelphi Real World Vitiligo Disease Specific Programme™ 2021, specifically, survey physicians their adult adolescent Physicians categorized by extent NSV at time completion mild, moderate or severe/very severe. Physician-reported patient information...
The criteria used by physicians to assess alopecia areata severity and its associated burden from the patients' point of view are not well understood. We aimed understand physician-assessed determinants disease severity, factors with patient-physician concordance, patient-reported severity. Data were drawn Adelphi Alopecia Areata Disease Specific Programme™, a point-in-time survey dermatologists their patients in real-world practice Japan conducted between January March 2021. Patients...
Alopecia areata (AA) is an autoimmune disease that causes scalp, face, and/or body hair loss. Recently, oral treatments with kinases inhibition became the first approved therapies for severe AA. An understanding of use and effectiveness traditional in real-world treatment settings needed to guide integration novel into paradigm. This study aimed describe patterns, dermatologists' reasons therapy choice, satisfaction control among patients Data were drawn from 2021–2022 Adelphi Real World AA...
This study evaluated the level of burden in pediatric and adolescent atopic dermatitis (AD) patients Japan, associated on caregivers/families, whether this varied with age.
A description of alopecia areata in European patients based on real-world survey data: physician-reported characterization severity and associated treatment utilizationBackground: Alopecia (AA), an autoimmune disease affecting the hair scalp, face, and/or body, can entail substantial psychological physical burden for patients.There is currently no international agreement how to treat AA approach may vary across countries.Objectives: This study investigated management clinical...
Vitiligo is a chronic autoimmune disease characterized by destruction of melanocytes, leading to skin depigmentation. can have high quality-of-life burden and profound impact on psychosocial well-being. The objectives this study were describe the self-reported patient among patients with nonsegmental vitiligo ≤ 10% affected body surface area, summarize physician-reported psychological lives, characteristics treatment history, goals, satisfaction. Data drawn from Adelphi Disease Specific...
Alopecia areata (AA) is characterized by non-scarring scalp and/or body hair loss and can negatively impact patient mental health. Data are limited on the alignment of physician perceptions AA severity with each other Japanese Dermatological Association (JDA) guideline criteria, patient-physician treatment satisfaction. Therefore, we performed analyses to compare JDA groupings disease explore satisfaction in Japan. were drawn from Adelphi Disease Specific Programme (DSP)™, a real-world...